Triple-negative breast cancer (TNBC) constitutes about 10-15% of all breast cancer cases with nearly 44,000 incident cases in the United States in 2023, as per Delveinsight’s estimates. It is a rare but aggressive form of breast cancer. Treatment for TNBC is more limited than for other breast cancer types.
Current Landscape of TNBC Treatment
Treatment can be challenging for TNBC. Without receptors, triple-negative tumors do not have the proteins they need to respond to common breast cancer treatments like hormone therapy and targeted therapy used for HR+/HER2- breast cancer. In patients with localized TNBC, dose-dense doxorubicin-cyclophosphamide, and paclit...
